NEW YORK (GenomeWeb News) — VistaGen will offer its stem cell-based screening platform with Capsant's cell culture system under a commercialization agreement focused on technologies for new programs that would use stem cell technologies to change the clinical trial process, VistaGen said today.
Vistagen's "Clinical Trials in a Test Tube" platform is aimed at generating predictive information about drug trial failures, particularly those involving liver and heart toxicity. Capsant's OrganDot 3D technology is a high-throughput, in vitro drug testing system using stem cell-based 3D tissue cultures.
VistaGen CEO Ralph Snodgrass said the agreement enables the two companies to offer "reproducible, mature, and functional human cells that grow as 3D 'micro-organs' in a commercially scalable platform with integrated analytical capabilities."
"This new agreement advances our common goal of providing new-generation drug development tools that are a vital necessity to improve drug R&D productivity in the pharmaceutical industry," he continued.
Capsant is headquartered in Southampton, UK, and VistaGen is based in South San Francisco.